Reata Pharmaceuticals has completed patient enrollment for Phase 3 of its CARDINAL study investigating the safety and efficacy of bardoxolone methyl (bardoxolone) for improving kidney function in people with Alport syndrome, the company announced. The Phase 3 part of the CARDINAL trial (NCT03019185), which has enrolled…
One year of treatment with Reata Pharmaceuticals’ bardoxolone methyl can reverse the damaging effects of Alport syndrome, promoting the recovery of kidney function, according to data from a Phase 2 trial. Similarly, data from another Phase 2 trial has shown that the investigative treatment can also lead to…
The European Commission (EC) has granted orphan drug status to bardoxolone methyl (bardoxolone)as a possible treatment for Alport syndrome, the therapy’s developer, Reata Pharmaceuticals, announced. Its effectiveness and safety are now being evaluated in a global clinical trial that’s enrolling patients with confirmed Alport syndrome and symptoms of kidney…
Reata Pharmaceuticals is investigating bardoxolone methyl as a potential treatment for chronic kidney disease (CKD) triggered by Alport syndrome. The CARDINAL (NCT03019185) Phase 2/3 clinical trial — which is currently recruiting patients — aims to determine the safety, tolerability and effectiveness of oral bardoxolone methyl in slowing, halting and possibly…
Get regular updates to your inbox.